Chromomycin A3
(Synonyms: 色霉素A3,Aburamycin B, CMA3, NSC 58514) 目录号 : GC43266A fluorescent probe and antitumor agent
Cas No.:7059-24-7
Sample solution is provided at 25 µL, 10mM.
Chromomycin A3 is an anthraquinone antibiotic and antitumor agent isolated from S. griseus that is used as a fluorescent probe for DNA with excitation/emission spectra of 445/575 nm.[1],[2] Its DNA binding is specific to two or more contiguous GC base pairs, which makes it suitable for characterizing heterochromatin in plants with species-specific AT:GC ratios.[2],[3] Chromomycin A3 is cytotoxic against non-small cell lung cancer and cervical cancer in vitro (IC50s = 1, 42, 60, and 40 nM for HCC44, A549, ME180, and HeLa cells, respectively).[4],[5] It also inhibits oxidative stress- and DNA damage-induced neuronal injury by enhancing Sp1 and Sp3 transcription factor binding.[6]
Reference:
[1]. Crissman, H.A., and Tobey, R.A. Methods in cell biology. 33, (1990).
[2]. Van Dyke, M.W., and Dercan, P.B. Chromomycin, mithramycin, and olivomycin binding sites on heterogeneous deoxyribonucleic acid. Footprinting with (methidiumpropyl-EDTA)iron(II). Biochemistry 22(10), 2373-2377 (1983).
[3]. Schwarzacher, T. Methods in molecular biology. 1370, (2016).
[5]. Miller, S.C., Huang, R., Sakamuru, S., et al. Identification of known drugs that act as inhibitors of NF-κB signaling and their mechanism of action. Biochem. Pharmacol. 79(9), 1272-1280 (2016).
[6]. Chatterjee, S., Zaman, K., Ryu, H., et al. Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann. Neurol. 49(3), 345-354 (2001).
Cas No. | 7059-24-7 | SDF | |
别名 | 色霉素A3,Aburamycin B, CMA3, NSC 58514 | ||
化学名 | (1S)-1-C-[(2S,3S)-7-[[4-O-acetyl-2,6-dideoxy-3-O-(2,6-dideoxy-4-O-methyl-α-D-lyxo-hexopyranosyl)-β-D-lyxo-hexopyranosyl]oxy]-3-[[O-4-O-acetyl-2,6-dideoxy-3-C-methyl-α-L-arabino-hexopyranosyl-(1→3)-O-2,6-dideoxy-β-D-arabino-hexopyranosyl-(1→3)-2,6-dideoxy- | ||
Canonical SMILES | C[C@H]1O[C@@](O[C@@H]2C[C@H](OC3=CC(C=C(C[C@]([C@H](OC)C([C@@H](O)[C@H](O)C)=O)([H])[C@H](O[C@]4([H])O[C@H](C)[C@@H](O)[C@H](O[C@]5([H])O[C@H](C)[C@@H](O)[C@H](O[C@@]6([H])C[C@@](O)(C)[C@@H](OC(C)=O)[C@H](C)O6)C5)C4)C7=O)C7=C8O)=C8C(O)=C3C)O[C@H](C)[C@@H] | ||
分子式 | C57H82O26 | 分子量 | 1183.3 |
溶解度 | 10 mg/ml in Ethyl Acetate; Soluble in DMSO; Soluble in Ethanol; | 储存条件 | Store at -20°C,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.8451 mL | 4.2255 mL | 8.4509 mL |
5 mM | 0.169 mL | 0.8451 mL | 1.6902 mL |
10 mM | 0.0845 mL | 0.4225 mL | 0.8451 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet